PCI Biotech Holding Balance Sheet Health
Financial Health criteria checks 6/6
PCI Biotech Holding has a total shareholder equity of NOK31.9M and total debt of NOK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NOK37.4M and NOK5.5M respectively.
Key information
0%
Debt to equity ratio
NOK 0
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 30.54m |
| Equity | NOK 31.91m |
| Total liabilities | NOK 5.51m |
| Total assets | NOK 37.41m |
Recent financial health updates
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Aug 05
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully
Apr 21We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely
Dec 16We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Apr 09PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans
Dec 22
Recent updates
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Aug 05We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully
Apr 21We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely
Dec 16We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Apr 09What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?
Feb 15PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans
Dec 22Financial Position Analysis
Short Term Liabilities: PCIB's short term assets (NOK36.9M) exceed its short term liabilities (NOK5.4M).
Long Term Liabilities: PCIB's short term assets (NOK36.9M) exceed its long term liabilities (NOK120.0K).
Debt to Equity History and Analysis
Debt Level: PCIB is debt free.
Reducing Debt: PCIB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PCIB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PCIB has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 9.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:01 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PCI Biotech Holding ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |